Edinburgh, UK, 14 February 2007 - Ardana plc (LSE:ARA) today announces preliminary results from a study in male subjects of its lead development compound, the GnRH antagonist Teverelix Long Acting (LA). This study, which is part of the ongoing clinical development of Teverelix LA for the treatment of advanced prostate cancer, is the first to be completed under a granted Investigational New Drug (IND) application for Teverelix LA.
